Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
More than 90% of people in the world own or use a mobile phone, and many of us couldn't live without them. We carry them everywhere we go, use them in bed and the bathroom, and for many people, they are the first thing they see in the morning.
Read Full NewsScreening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.
At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.
Combination therapies remain key as multiple agents for melasma hit the market.
CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.
For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.
A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.
Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.
1.
Benzene in Cold Med; Male Cancer Death to Rise 93%; Mail-Order Drugs Compromised?
2.
'Full House' Star's Cancer; Fluoride Fears Go Mainstream; Florida Doctor Arrested
3.
Belzutifan for Advanced Renal Cell Carcinoma is approved by the FDA.
4.
According to the Lancet, having cancer and VTE at the same time increases mortality risk.
5.
Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma
1.
Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer
2.
Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment
3.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
4.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
5.
Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
3.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
4.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
5.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge